Razzaq R, O'Halloran D J, Beardwell C G, Shalet S M
Department of Clinical Endocrinology, Christie Hospital, Manchester, UK.
Horm Res. 1993;39(5-6):218-22. doi: 10.1159/000182739.
CV205-502 is a new non-ergot dopamine agonist currently being studied for the treatment of hyperprolactinaemia. We have assessed the effects of CV205-502 on prolactin secretion and the clinical consequences of hyperprolactinaemia in 16 patients with hyperprolactinaemia who had previously been unsuccessfully treated with bromocriptine. These patients had been either intolerant of and/or resistant to the effects of bromocriptine. Sixteen patients, all women in an age range between 20 and 49 years (mean 31.5 years), were treated for periods of between 8 and 52 weeks with doses of CV205-502 ranging from 0.075 to 0.3 mg taken once daily at night. Seven out of 10 of the patients, who were intolerant of bromocriptine, tolerated CV205-502 better with fewer side effects although the nature of the side effects was similar to that associated with bromocriptine. Only 1 patient from this group stopped taking CV205-502 due to side effects. Six of 11 patients exhibiting bromocriptine resistance showed a significant reduction in the degree of hyperprolactinaemia but normoprolactinaemia was achieved in only 1. Galactorrhoea ceased in 2 of 6 patients, menstruation resumed in 6 of 11 patients presenting with amenorrhoea, and 2 patients conceived. In patients with bromocriptine intolerance and/or resistance, CV205-502 is useful as a second line treatment.
CV205 - 502是一种新型非麦角多巴胺激动剂，目前正在进行治疗高泌乳素血症的研究。我们评估了CV205 - 502对16例高泌乳素血症患者泌乳素分泌的影响以及高泌乳素血症的临床后果，这些患者之前使用溴隐亭治疗未成功。这些患者对溴隐亭不耐受和/或耐药。16例患者均为女性，年龄在20至49岁之间（平均31.5岁），接受了为期8至52周的治疗，每晚服用一次CV205 - 502，剂量范围为0.075至0.3毫克。10例对溴隐亭不耐受的患者中，有7例对CV205 - 502耐受性更好，副作用更少，尽管副作用的性质与溴隐亭相关的副作用相似。该组中只有1例患者因副作用停止服用CV205 - 502。11例对溴隐亭耐药的患者中有6例高泌乳素血症程度显著降低，但只有1例实现了泌乳素正常。6例患者中有2例溢乳停止，11例闭经患者中有6例月经恢复，2例患者怀孕。对于溴隐亭不耐受和/或耐药的患者，CV205 - 502作为二线治疗是有用的。
